Shots: The approval is based on the P-lll BELIEVE study assessing Reblozyl (luspatercept) + BSC vs PBO + BSC in adult patients with anemia associated with beta-thalassemia requiring regular RBC […]readmore
Tags : Reblozyl
The US FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA […]readmore
Shots: The approval is based on P-III BELIEVE study assessing Reblozyl (1.0 mg/kg, SC) + BSC vs PBO + BSC in 336 patients in a ratio (2:1) requiring RBC transfusions […]readmore